Cargando…

Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II)

OBJECTIVE: To describe survival of patients with hepatic encephalopathy (HE), up to 5 years after initiation of rifaximin-α (RFX) treatment. DESIGN/METHOD: A retrospective, observational extension study within 9 National Health Service secondary/tertiary UK care centres. All patients had a clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aspinall, Richard J, Hudson, Mark, Ryder, Stephen D, Richardson, Paul, Farrington, Elizabeth, Wright, Mark, Przemioslo, Robert T, Perez, Francisco, Kent, Melanie, Henrar, Roland, Hickey, Joe, Shawcross, Debbie L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Liver
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086718/ https://www.ncbi.nlm.nih.gov/pubmed/37056320 http://dx.doi.org/10.1136/flgastro-2022-102221

Ejemplares similares

The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS)
por: Hudson, Mark, et al.
Publicado: (2017)

Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
por: Hudson, Mark, et al.
Publicado: (2019)

Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
por: Nishida, Shinya, et al.
Publicado: (2019)

Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study
por: Kawaratani, Hideto, et al.
Publicado: (2022)

Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH)
por: Jiménez, César, et al.
Publicado: (2022)

Long-term Outcomes After Controlled Oxygenated Rewarming of Human Livers Before Transplantation
por: Hoyer, Dieter P., et al.
Publicado: (2020)

Long-term Outcome of Endoscopic and Percutaneous Transhepatic Approaches for Biliary Complications in Liver Transplant Recipients
por: Rönning, Jesper, et al.
Publicado: (2019)

Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy
por: Ishikawa, Toru, et al.
Publicado: (2020)

Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy
por: Fujiwara, Yudai, et al.
Publicado: (2021)

Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis—the first 24 h
por: McPherson, Stuart, et al.
Publicado: (2016)

Deprescribing medications that may increase the risk of hepatic encephalopathy: A qualitative study of patients with cirrhosis and their doctors
por: Williams, Sydni, et al.
Publicado: (2021)

Long-term Prognosis and Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: A Single-Center Experience
por: Ueda, Yoshihide, et al.
Publicado: (2017)

How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist
por: Shawcross, Debbie L., et al.
Publicado: (2016)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

Outcomes of Liver Transplant Recipients With Autoimmune Liver Disease Using Long-Term Dual Immunosuppression Regimen Without Corticosteroid
por: Satapathy, Sanjaya K., et al.
Publicado: (2017)

Short- and Long-term Outcomes of De Novo Liver Transplant Patients Treated With Once-Daily Prolonged-Release Tacrolimus
por: Okumura, Yuichiro, et al.
Publicado: (2017)

Long-term Outcome of Orthotopic Liver Transplantation in Patients With Hemochromatosis: A Summary of a 30-year Transplant Program
por: Dobrindt, Eva Maria, et al.
Publicado: (2020)

Long-term Follow-up of a Randomized Trial of Tacrolimus or Cyclosporine A Microemulsion in Children Post Liver Transplantation
por: Lloyd, Carla, et al.
Publicado: (2021)

Low Titers of Antidonor ABO Antibodies After ABO-Incompatible Living Donor Liver Transplantation: A Long-Term Follow-Up Study
por: Ueda, Daisuke, et al.
Publicado: (2018)

Hepatitis B in pregnancy
por: Dyson, Jessica Katharine, et al.
Publicado: (2014)

Age Matching of Elderly Liver Grafts With Elderly Recipients Does Not Have a Synergistic Effect on Long-term Outcomes When Both Are Carefully Selected
por: Gilbo, Nicholas, et al.
Publicado: (2019)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study
por: Friman, Styrbjörn, et al.
Publicado: (2021)

Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia
por: Larrey, Dominique, et al.
Publicado: (2022)

Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)

Impact of the Trough Level of Calcineurin Inhibitor on the Prevalence of Donor-Specific Human Leukocyte Antigen Antibodies During Long-Term Follow-Up After Pediatric Liver Transplantation: Antibody Strength and Complement-Binding Ability
por: Tokodai, Kazuaki, et al.
Publicado: (2017)

An Unusual Presentation of Posterior Reversible Encephalopathy Syndrome Following Liver Transplantation
por: Rajakumar, Akila, et al.
Publicado: (2022)

Long-term Outcomes of ABO-incompatible Pediatric Living Donor Liver Transplantation
por: Honda, Masaki, et al.
Publicado: (2018)

Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites
por: Yokoyama, Keiji, et al.
Publicado: (2022)

Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community
por: Chalmers, Jane, et al.
Publicado: (2019)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
por: Kimer, Nina, et al.
Publicado: (2014)

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy
por: Jesudian, Arun B., et al.
Publicado: (2020)

Liver‐related long‐term outcomes of thiazolidinedione use in persons with type 2 diabetes
por: Yen, Fu‐Shun, et al.
Publicado: (2020)

Patient understanding of liver cirrhosis and improvement using multimedia education
por: Goldsworthy, Matthew A, et al.
Publicado: (2017)

In vitro efficacy of pro‐ and anticoagulant strategies in compensated and acutely ill patients with cirrhosis
por: Lisman, Ton, et al.
Publicado: (2018)

The Psychological and Financial Impact of Long-distance Travel for Liver Transplantation
por: Peretz, David, et al.
Publicado: (2020)

Mesenchymal iron deposition is associated with adverse long‐term outcome in non‐alcoholic fatty liver disease
por: Eder, Sebastian K., et al.
Publicado: (2020)

Non‐invasive diagnosis of cirrhosis and long‐term disease monitoring by transient elastography in patients with Wilson disease
por: Paternostro, Rafael, et al.
Publicado: (2020)

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Bajaj, Jasmohan S., et al.
Publicado: (2013)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1li0dkqglcev5dnhe8ur649g57